

RNA-seq analysis: primary breast tumour and circulating tumour cells

Dominik Hadzega ^{1,2}, Gabriel Minarik ¹, Andrea Soltysova ^{3,4}, Nemcová Petra ¹, Katarina Kalavska ⁵, Marian Karaba ⁶, Juraj Benca ^{6,7}, Tatiana Sedlackova ¹, Daniel Pindak ⁶, Lubos Klucar ^{2#}, Michal Mego ^{5,8#}

¹Medirex Group Academy n.p.o., Nitra

²Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovakia

³Biomedical Research Center of the Slovak Academy of Sciences, Bratislava, Slovakia

⁴Department of Molecular Biology, Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia

⁵Translational research unit, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia

⁶Department of Oncosurgery, National Cancer Institute, Bratislava, Slovakia

⁷Department of Medicine, St. Elizabeth University, Bratislava, Slovakia

⁸2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia

authors share last authorship

Introduction

In metastatic disease of Breast cancer, cells with origin in the primary tumour are able to migrate to distant organ sites to seed meta-static tumours. These cells, so called circulating tumour cells (CTC) are suspected to be produced more easily by tissues of mesenchymal characteristics. We analysed RNA-sequencing from primary tumour samples of patients with breast cancer. We were looking for changes in gene expressions in primary tumour tissue of the patients with the CTC with mesenchymal characteristics detected in their blood compared to the patients without CTC in blood. To uncover the biological context, the list of differentially expressed genes we gained by analysis was further used for gene enrichment analysis.

Methods

Samples

17 patients - primary tumour samples
8 patients: CTC EMT detected in blood
9 patients: CTC- (not detected in blood)

RNA-seq (Illumina)

2x 75 nt (pair end)

RNA-seq reads analysis pipeline

Raw reads > Trimmomatic > BWA for short reads > FeatureCounts

Statistical comparison

Tool: Deseq2 (R)


Comparison between tumor tissue of patients with mesenchymal CTC (8 patients) & tumor tissue of patients without CTC in blood (9 patients).

Pathway and GO analysis

Tools: g:Profiler

Results

By RNA-seq analysis, we found 70 genes to be up-regulated and 17 to be down-regulated, under the conditions of adjusted p-value<0.1 and fold change>2. These results are shown on the Table 1. Pathway analysis showed down-regulated genes to be often associated with immunology related pathways. Otherwise, differentially expressed genes showed connection to various signaling pathways and interaction between cells. Detailed results are shown on Figure 2.



| Up-regulated | | Down-regulated |
|--------------|--------------|----------------|
| CARTPT | RASD1 | LINC01953 |
| KRT5 | PNMA8B | TRH |
| KRT14 | INTS4P2 | PGAP3 |
| DSC3 | ALCAM | MIEN1 |
| ALDH1A2 | INTS4 | ERBB2 |
| IRX1 | MYOZ1 | TMEM156 |
| KCTD21-AS1 | LOC107986399 | PSMD3 |
| KIT | GRIA1 | RHOH |
| KCNE4 | TRIM29 | STARD3 |
| CALML3 | GRIK1 | MARK1 |
| TSPAN5 | SCN5A | GRB7 |
| ACTN2 | CLDN8 | MED24 |
| KRT17 | TUBB4A | MUC19 |
| TAT | JUN | MYBL2 |
| SCGB3A1 | ALG8 | UBD |
| RCAN1 | ROCR | IGF1R |
| C10orf90 | HPSE2 | FAM83B |
| FERMT1 | PGAP1 | |
| CLDN11 | CLNS1A | |
| GAB2 | NCAM1 | |
| GPC3 | GDF10 | |
| VEPH1 | NLGN1 | |
| FMN2 | COL17A1 | |
| GEM | SPHKAP | |
| LRFN5 | PCK1 | |
| LINC02813 | LOC107984270 | |
| SMYD1 | LOC107984268 | |
| LOC100129434 | NDUFC2 | |
| LOC107986984 | PAAF1 | |
| ZNF483 | ITIH5 | |
| SOX10 | CST5 | |
| APOD | OVCH2 | |
| GRIN2A | DUSP1 | |
| OSR1 | LOC105371267 | |
| INSYN2B | TP63 | |

Table 1: Differentially expressed genes in primary tumours. Comparison between tumor tissue of patients with CTC with mesenchymal characteristics & tumor tissue of patients without CTCs in blood (adjusted p value<0.1).

Conclusions

We identified genes with distinct expression profiles in primary tumours of patients containing CTC with mesenchymal characteristics in their blood compared to patients lacking CTC in their blood. These genes have potential as markers of more aggressive disease, treatment targets (in condition of further validation study). Previous studies of genes show their roles in various cancer related processes. Gene enrichment analysis proposes pathways involved in the processes related to CTC production and subsequent metastasis. Results of RNA-seq study were further compared by DNA microarray and qRT-PCR. These results (not showed here) will be published soon.

To better understand processes influencing CTC production ongoing in primary tumour, we propose further study by single-cell approach.




Figure 2: Results of pathways enrichment analysis by g:Profiler.

Acknowledgements

This work was funded by APVV-16-0010 (Slovak Research and Development Agency) project and the OPII programme as the project PROMEDICOV-19, code ITMS: 313011ATA2, co-financed by the ERDF.

Genes

RNA-seq analysis: primary breast tumour and circulating tumour cells

Dominik Hadzega (Medirex Group Academy n.p.o., Nitra / Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava), Gabriel Minarik (Medirex Group Academy n.p.o., Nitra), Andrea Soltysova (Biomedical Research Center SAS, Bratislava / Department of Molecular Biology, FNS, Comenius University, Bratislava), Petra Nemcova (Medirex Group Academy n.p.o., Nitra), Katarina Kalavska (Translational research unit, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava), Marian Karaba (Department of Oncosurgery, National Cancer Institute, Bratislava), Juraj Benca (Department of Oncosurgery, National Cancer Institute / Department of Medicine, St. Elizabeth University, Bratislava), Tatiana Sedlackova (Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava), Daniel Pindak (Department of Oncosurgery, National Cancer Institute, Bratislava), Lubos Klucar (Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava) and Michal Mego (2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava).

Abstract:

Circulating tumour cells (CTC) are cells with origin in tumour tissue, which are able to leave their original tissue and travel to distant organs, where they can establish new metastasis. Epithelial to mesenchymal transition (EMT) is believed to influence cells' ability to become CTC. In our research we studied gene expressions in breast tumour and normal breast tissue of breast cancer patients. We investigated which genes expressions are altered for tissue of patients with CTC EMT (positive on mesenchymal markers) in their blood. Gene expressions were obtained by whole transcriptome RNA-sequencing of the fresh frozen primary tumour samples. The study included 18 patients with primary breast cancer and 5 donors of normal breast tissue. We used standard procedure for differentially expressed genes analysis (using tools in Galaxy and R environments) and then used set of differentially expressed genes for gene enrichment analysis in purpose of relevant pathways identification. From RNA-seq analysis, we found 70 genes to be up-regulated and 17 to be down-regulated, under the conditions of adjusted $p\text{-value} < 0.1$ and $\log_2FC > 1$. Downregulated genes were showed to be related to immunology, while up-regulated genes to various signalling pathways and cell-cell interactions. This research was funded by APVV-16-0010 project and the OPII programme as the project PROMEDICOV-19, code ITMS: 313011ATA2, co-financed by the ERDF.